Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2019

View Archived Issues

Naive B cells have tell-tale signature in lupus

UCB studies rozanolixizumab in phase III for generalized myasthenia gravis

Pact Pharma initiates first-in-human study of NeoTCR-P1 in solid tumors

Pfizer initiates phase II study of PF-06826647 for the treatment of plaque psoriasis

Patient recruitment ongoing in phase I study of CPI-200

mR-21 as potential prognostic biomarker and therapeutic target in hypertensive heart disease

[89Zr]-Daratumumab as a promising new agent for CD38-targeted imaging of myeloma

Tracer quantification and assessment of tumor uptake of [18F]afatinib in NSCLC

NDFIP1 may be a novel target for prevention and treatment of Parkinson's disease

CEPI and WBVR partner on vaccine for Rift Valley fever

Hydra's opposite: researchers identify broad resistance mechanism to narrowly targeted therapies

Lundbeck describes new PDE1 inhibitors

New adenosine A2A receptor antagonists presented by Adorx Therapeutics

NodThera discovers NLRP3 inflammasome inhibitors

Roche discloses new gamma-secretase inhibitors

ReViral patents respiratory syncytial virus fusion inhibitors

New genetic variants found in individuals with disorders of sexual development

FDA clears HOOKIPA's IND for phase I/II trial of HB-201 for HPV-positive cancers

Novartis and Amgen discontinue pivotal studies of CNP-520 for Alzheimer's disease

Interim phase Ib data on ACI-24 to treat Alzheimer's disease-like symptoms in Down syndrome

New hamster model of carotid artery atherothrombotic occlusion developed

Faron offers update from phase I/II MATINS study of Clevegen in advanced solid tumors

First patient enrolled in phase I study of GST-HG-161

Study in humans determines biodistribution of COX-1 PET radioligand [11C]PS-13

Beta Pharma enrolling patients with NSCLC for phase III trial of BPI-7711

Human biodistribution and dosimetry of the PET imaging agent [11C]trimethoprim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...